Rhythm Pharmaceuticals Inc. (RYTM) carries a Roarable Rating of C- (Hold) with 60/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Rhythm Pharmaceuticals Inc. (RYTM) advanced +1.20% to $93.07 as options desks priced 56% call premium vs. 44% put protection around the $91 max-pain magnet. Solid 90% profit margin (-30% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
CAMP4 Therapeutics Corporation (CAMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CHICAGO, October 21, 2026--William Blair today announced that Alethia Young has initiated coverage of 13 biotechnology companies, marking the next step in the firm’s continued expansion of its biotech offering.
Rhythm Pharmaceuticals (NASDAQ:RYTM) has outperformed the market over the past 5 years by 40.37% on an annualized basis producing an average annual return of 51.51%. Currently, Rhythm Pharmaceuticals has a market
BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine dis
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +45.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on RYTM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for RYTM. Explore sector supply chains on /butterfly.
Why RYTM Stock advanced +1.20% Today — RQD Quant Desk Flash. Solid 90% profit margin (-30% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.